Who makes Apo-Oxycodone CR®?

Apo-Oxycodone CR® is developed by Centre for Addiction and Mental Health.

What development phase is Apo-Oxycodone CR® in?

Apo-Oxycodone CR® is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

Apo-Oxycodone CR®

Centre for Addiction and Mental Health · FDA-approved active Small molecule Quality 0/100

Apo-Oxycodone CR® is a marketed controlled-release oxycodone product developed by the Centre for Addiction and Mental Health. The key composition patent expires in 2028, providing a period of exclusivity that supports its market position. The primary risk is the lack of disclosed revenue data and key trial results, which may limit investor confidence and competitive insights.

At a glance

Generic name	Apo-Oxycodone CR®
Also known as	Oxycodone
Sponsor	Centre for Addiction and Mental Health
Modality	Small molecule
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Abuse Liability of Controlled-Release Oxycodone Formulations (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Apo-Oxycodone CR® CI brief — competitive landscape report
Apo-Oxycodone CR® updates RSS · CI watch RSS
Centre for Addiction and Mental Health portfolio CI